Progress in the development of immunotherapy for the treatment of patients with cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 11902815.
- Also identified by PMC identifier 2413437.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Several recent developments have hallmarked progress in tumour immunology and immunotherapy. The use of interleukin-2 (IL-2) in cancer patients demonstrated that an immunological manipulation was capable of mediating the regression of established growing cancers in humans. The identification of the genes encoding cancer antigens and the development of means for effectively immunizing patients against these antigens has opened important new avenues of exploration for the development of effective active and cell-transfer immunotherapies for patients with cancer.
Medical subject headings
- Antineoplastic Agents
- Immunotherapy
- Interleukin-2
- Neoplasms